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When disposition is monoexponential, extravaseular concentration-time (C, t) data yield both 
disposition and absorption parameters, the latter via the Wagner-Nelson method or deconvolution 
which are equivalent. Classically, when disposition is multiexponential, disposition parameters are 
obtained from intravenous administration and absorption data are obtained from extravascular 
C, t data via the Loo-Riegelman or Exact Loo-Riegelman methods or via deconvolution. Thus, 
in multiexponential disposition one assumes no intrasubject variation in disposition, a hypothesis 
that has not been proven for most drugs. Based on the classical two- and three-compartment open 
models" with central compartment elimination, and using postabsorptive extravascular C, t data 
only, we have developed four equations to estimate kw when disposition is biexponential and two 
other equations m estimate kw when disposition is triexponentiaL The other disposition rate 
constants are readily obtained without intravenous data. We have analyzed extravascular data of 
flurbiprofen (12 sets), mesoridazine (20 sets), flunarizine (5 sets), labetalol (9 sets), and 
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diazepam (4 sets). In the case of diazepam intravenous C, t data were also available for analysis. 
After disposition parameters had been estimated from the extravascular data the Exact Loo- 
Riegelman method with the Proost modification was applied to the absorptive extravascular data 
to obtain AT/Vp as a function of time. These latter data for each subject and each drug studied 
were found to befitted by a function indicating either simple first-order absorption, two consecutive 
first-order processes, or zero-order absorption. After absorption and disposition parameters had 
been estimated, for each set of extravascular data analyzed, a reconstruction trend line through 
the original C, t data was made. The new methods allow testing of the hypothesis of constancy of 
disposition with any given drug. There is also a need for new methods of analysis since the majority 
of drugs have no marketed intravenous formulation, hence the classical methods cannot be applied. 
KEY WORDS: compartment models; disposition; absorption; mesoridazine; flurbiprofen; 
flunarizine; labetalol; diazepam. 
INTRODUCTION 
Compartment analysis has been and still is the most common approach 
to pharmacokinetic characterization of a drug in the body (1-3). Usually 
such a system of compartments has no anatomic or physiological reality. 
For those compartments involved in disposition of the drug the rates of 
transfer between compartments is assumed to obey first-order kinetics if the 
system is linear. It is not necessary to assume first-order kinetics for transfer 
of drug from an extravascular absorption site to the systemic circulation. 
The purposes of pharmacokinetics are (i) to reduce data to meaningful 
numbers or parameters, (ii) to use the reduced data to make predictions of 
results of future experiments or predictions of results of a host of studies 
that would be too costly and time-consuming to be carried out (2), (iii) to 
allow quantitative correlation with pharmacodynamic effects, and (iv) to 
provide pharmaceutical scientists with quantitative methods to determine 
the effects of formulation factors on performance of dosage forms of drugs 
in animals and human beings. 
To perform item (iv) above one usually requires absorption plots, and, 
classically, these have been obtained by methods outlined below. When 
disposition is monoexponential one estimates the first-order elimination rate 
constant from postabsorptive concentration-time data and then applies the 
Wagner-Nelson method (4) to data in the absorptive phase to obtain values 
of A-r~ V (amount of drug absorbed to time T divided by the volume of 
distribution) as a function of time. Frequently, but not always, these values 
can be fitted to one of the absorption functions listed below in order to 
estimate one or more absorption rate constants. As a result of intrasubject 
variation of the elimination rate constant (~.~) of many drugs it is our opinion 
that this disposition parameter should not be estimated from data derived 
from a different treatment than the data being analyzed for absorption. 
Classically, when disposition is bi- or triexponential the drug has been 
administered intravenously first, then extravascularly second. There have 
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been two approaches: (i) Compartment model disposition parameters have 
been derived from the intravenous data, then these used in application of 
either the Loo-Riegelman method (5) or the Exact Loo-Riegelman method 
(6), as modified by Proost (7), to obtain values of AT/Vp (amount of drug 
absorbed to time T divided by the volume of the central compartment) as a 
function of time; or, (ii) deconvolution is applied (8-11) using both the 
intravenous and extravascular data. Again, the AT/Vp vs. time data may 
frequently be fitted to an absorption function similar to one of those listed 
below and one or more absorption rate constants estimated. 
The methods described above, which use intravenous data to evaluate 
extravascular data, involve the assumption that there is constancy of disposi- 
tion parameters of the drug. This constitutes an hypothesis and there is 
evidence with many drugs that this hypothesis has to be rejected (12-29). 
Some authors (14,16) have reported areas under concentration-time curves 
(A UC), while others have reported elimination half-lives (12,14,17) follow- 
ing administration of multiple single doses and have calculated measures of 
intra- and intersubject variation. We believe that clearances, rather than 
A UCs, and elimination rate constants, rather than half-lives, should be ana- 
lyzed for intra- and intersubject variation. We have reevaluated those data 
and have added evaluations of similar data (12-29) using the method out- 
lined in Table I, where the intrasubject coefficient of variation (CV) has 
been estimated for each subject from the four oral clearances measured on 
Days 2, 8, 16, and 21 ; the lowest, highest, and median CVs are then obtained 
and are reported in Table II. The grand mean parameter value and the 
intersubject CV is estimated from the subject means as indicated in Table I 
and these are also shown in Table II. The intrasubject variation in the 
pharmacokinetic parameters listed in Table II may be the result of intrasub- 
ject variation in distribution and/or elimination. The data in Table II indi- 
cate a wide range in intrasubject variabilities. The first two rows of Table II 
Table I. Example of Method of Calculation of Intra- and Intersubject Coefficients of Variation: 
Oral Clearance of Verapamil" 
Oral clearance of verapamil (L/min) Subject Intrasubject 
Subject Day 2 Day 8 Day 16 Day 21 X CV(%) 
1 2.53 2.42 3.01 2.31 2.57 12.0 Lowest 
2 5.22 4.06 4.69 10.43 6.10 48.0 Highest 
3 3.71 4.51 2.72 3.15 3.52 22.0 
4 2.09 2.38 2.57 1.74 2.20 16.5 Median 
5 4.17 3.76 3.14 3.18 3.56 t3.9 
Grand .~ 3.59 
Intersubject CV (%) =42.4 
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show that the systemic clearance of furosemide and the oral clearance of 
flurbiprofen have median and highest intrasubject CVs which are lower than 
the intersubject CVs. However, in the 22nd row one can see that for the A,1 
of phenylbutazone the median and highest intrasubject CVs of 71.8 and 
110%, respectively, are considerably higher than the intersubject CV of 
35.6%. In 19 of the 36 examples in Table II the median intrasubject CV is 
greater than the intersubject CV. 
Here we develop several methods to estimate disposition parameters of 
the classical two- and three-compartment disposition models from postab- 
sorptive extravascular (oral, im, subcutaneous, etc.) data without the need 
for intravenous data. 
The purposes of this article are (i) to describe the new methods to 
estimate classical two- and three-compartment disposition parameters from 
postabsorptive plasma (serum or whole blood) concentration-time data; (ii) 
to illustrate application of these methods to extravascular data of flurbipro- 
fen, mesoridazine, flunarizine, labetalol, and diazepam, and present results 
of these pharmacokinetic analysis; (iii) to illustrate application of the Exact 
Loo-Riegelman method (6) with the Proost modification (7) to concentra- 
tion-time data in the absorptive phase of the same data sets and present 
results of fitting Av/lip or fraction absorbed values to obtain the kinetics of 
absorption; and (iv) to show how results from (ii) and (iii) may be combined 
to allow reconstruction of the original concentration-time data. 
EXPERIMENTAL 
Format 
Method 1 is the classical one where intravenous data are fitted with a 
bi- or triexponential equation and disposition rate constants are estimated 
from the coefficients and exponents of such equations by methods previously 
described (2,3). 
In the Equations section below, equations needed to apply Methods 2, 
3, 4, and 5 are given. The two-compartment open model and biexponential 
disposition is considered first, followed by the three-compartment open 
model and triexponential disposition. A Source of Equations section follows 
and the origins of the equations in the Equations section are given. These 
sections are followed by a section giving details of Applications of the Equa- 
tions to extravascular data of specific drugs. 
Methods 3 and 5 involve direct computer fitting of postabsorptive con- 
centration-time data. If one uses the microcomputer program MINSQ (30) 
and the SIMPLEX method is initially used then no initial estimates of the 
parameters are required. Nonlinear least squares should always be the final 
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method used. Methods 2 and 4 are most suited for cases where there has 
been zero-order input over a time v and hence the mean input time, MIT, 
is known, namely r/2. 
Equations 
The classical two-compartment open model is shown in Scheme 1. 
klo 
#2 
Scheme 1. The two-compartment open model. 
For Methods 2, 3, 4, and 5 postabsorptive concentration-time data are 
initially computer-fitted to Eq. (1) 
C=BI e-X't+B2 e -&t (~,1 <~,2) (1) 
Method 2 
k,0=~l +~2-2IA2(MRT) (2) 
k2~- (3) 
klo 
k l 2 = ~ l  + ~ 2 - k l O - k 2 1  (4) 
where M R T =  (A UMC/A UC) - M I T  (see Glossary). 
Method 3A 
Postabsorptive concentration-time data are computer fitted to Eq. (5) 
using the AUC from Eq. (6) and ,~ and ~z from Eq. (1) as constants and 
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km and ts as estimated parameters. 
C -  A U C  [Al(Z2-klo) e-X~(t-t~ e -&(~-ts)] (5) 
~2 - ,~1 
A UC= C dt + ~T/Z1 (6) 
The C-r of Eq. (6) is given by Eq. (7), where T is the last sampling time. 
CT = B1 e-Zlr+ B2 e -A2T  (7) 
Method 3B 
Postabsorptive concentration-time data are computer fitted to Eq. (5) 
with ,~, ~2, k~o and ts as estimated parameters, again using A UC from Eqs. 
(6) and (7) as a constant. 
Method 4 
This method assumes that the dose is absorbed at a zero-order rate over 
time r; postabsorptive concentration-time data are treated like postinfusion 
data and r is the time shift required to do this. 
(,~2 - )~I)(T)(B~) 
k10=,~2 (8) 
(A UC)(e +~:- 1) 
Method 5 
This method makes the same assumption as in Method 4. Postabsorp- 
tive concentration-time data are computer fitted to Eq. (9) with Z~, 2~2, and 
A UC as constants and km and r as estimated parameters. Note that Z1 and 
~2 are obtained in the initial fitting to Eq. (1). 
C -  AUC(Z2-k l~  ~ : -  l) e-~"-~ A U C ( k l ~  ZO(e+ Z : -  l) e-Z2~ (9) 
( & -  ~.~)r (Z2- Z,)r 
In Methods 3A, 3B, 4, and 5 once kl0 has been estimated then k2t and 
kj2 are obtained from Eqs. (3) and (4) using ~ and/1.2 from the fit to Eq. 
(1). 
The classical three-compartment open model is shown in Scheme 2. 
l 'l  -ili 12' ' l 3il - 1 ~ k l o  
Scheme 2. The three-compartment open model. 
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For Methods 3A, 3B, and 5 postabsorptive concentration-time data are 
initially computer fitted to Eq. (10). 
C = Bl e-  ~'t + B2 e -  &t + B3 e-L3 t (I0) 
Method 3A 
Postabsorptive concentration-time data are computer-fitted to Eq. (11) 
with 21, 22, and X3 from Eq. (10) and AUC from Eqs. (6) and (7) as 
constants and kin, Z, ts as estimated parameters. Z is the sum k21 + k31. 
e 
(& - ; q )  ( 2 ~  - 21) 
C= A UC 4 (k10(2~ - ZAa) + 212223) -~2(,-to e (11) 
('/~1 - -  22)(23 - -  )~1,2) 
or (klo(2 2 _ Z ~ 3 )  + ~1~223 ) e - z~(t- ,0 
(1]'1 -- 23)(22 -- 23) 
Method 3B 
Postabsorptive concentration-time data are computer-fitted to Eq. (11) 
with A UC [from Eqs. (6) and (7)] as a constant and ,~1,22, 23, kl0, Z, and 
ts as estimated parameters. 
Method 5 
This method assumes that the dose is absorbed at zero-order rate over 
time r; postabsorptive concentration-time data are treated like postinfusion 
data and ris the time shift required to.do this. Postabsorptive concentration- 
time data are computer-fitted to Eq. (12) with ,~1, 22, ,~3, and AU C as 
constants and kin, and Z =  k2~ + k31 as estimated parameters. 
C -  A UC(klo(~ l  - Z )  + 22~3)(e +)q~-  1) e_Z, r 
(& - & )  ( ,~3 - ; q ) r  
-~ A U C ( k l o ( ~ 2 -  Z )  + 21/~3)(e +'~2r- 1) -z2t 
e 
(21 -- 22)(23--  22) T 
A UC(klo(2s-  Z )  + 21Z2)(e +;t;r- 1) -x,, 
+ e (12) 
(~1 - 23)(~2- 23)r 
A U M C / A  UC 
A U M C / A  UC for the extravascular data is estimated directly from the 
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data using Eq. (13) of Yamaoka et al. (31) .  
AUMC STtC" dt+eT" T+CT 
- -  - (13)  
A UC A UC 
In Eq. (13) AUC is obtained with Eq. (6) and ~'r with Eq. (7). The 
integrals in Eq. (6) and in Eq. (13) were estimated with a combination of 
the linear and logarithmic rules using the criterion of Proost (7) to choose 
which rule to use at a specific place in the data set. 
Methods 2 and 4 cannot be satisfactorily applied to the model of Scheme 
2 after addition of extravascular input. 
Source  o f  Equat ions  
Source of  Eq. (2) 
For the model of Scheme 1, Wagner (32) showed that Eq. (14) held. 
MRT= ,~1 + ~.2 - kl0 (14) 
Rearrangement of Eq. (14) yields Eq. (2). The extravascular A UMC/ 
A UC is the sum of two mean residence time functions as indicated by Eq. 
(15). 
A UMC/A UC = MRT+ MIT (15) 
Hence, 
MRT= A UMC/A UC- MIT (16) 
Source of Eq. (5) 
For the model of Scheme 1 and bolus intravenous administration the 
concentration, C, in compartment 1 is given by Eq. (17) (2,3). 
C -  Co {(k2,-~.,) e-Z't-(k21-)~2) e -~2'} (17) 
Now 
Co = k,o . (AUC) (18) 
Substituting for Co in Eq. (17) from Eq. (18) followed by use of Eq. 
(3) leads to Eq. (5). 
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Source of Eq. (8) 
For the model of Scheme 1 where there is zero-order input at the rate 
ko over time r into compartment 1 the concentration, C, in compartment 1 
when t _  r is given by Eq. (19) (2,3). 
c_ko(k2:-40(e +<~- 1) e_<,_~ ko(k21- 42)(e +'~2r- 1) e_Z= ~ (19) 
,~ , (&-  4,)  v. &(,~,~ - &)vp  
If we apply Eq. (19) to extravascular data and let the coefficient of the 
4~ term be B~ then B~ is given by Eq. (20). 
k0(k,l - 41)(e +<~- 1) 
B~ - (20) 
/].1 (42 -- 41) Vp 
Now 
ko D Co klo(A UC) 
- - =  (21) 
vp rvp r r 
Substituting for ko/Vp in Eq. (20) from Eq. (21) gives 
B: =klo(AUC)(k2,-4~)(e +z'~- 1)_ (AUC)(42-km)(e +<'- 1) (22) 
hence 
r(;~, - 4,)  v~ r(4, - ~.,) 
( 4 2 -  4 0 ( 0 ( ~ 0  
4 , - k l o -  (23) 
(AUC)(e + ~ -  1) 
Rearrangement of Eq. (23) gives Eq. (8). 
Source of Eq. (11) 
The concentration, C, in the central compartment of the model of 
Scheme 2 after bolus intravenous administration is given by Eq. (24) (3). 
~(/~., - 4 : ) ( ~ 3 ,  - 4 , )  e -  ~" + (/~.1 - 4 . ) ( ~ 3 ,  - 4 . )  C= Co e 22t 
( (A2- 4a)(43- Aq) (4 , -4 , ) (43 -4 , )  
(k21 - 43)(lc3~- 43) e-  ~3tl (24) 
(4, - 43) (4 . -  43) J 
Substituting for Co in Eq. (24) from Eq. (18), letting Z=k2~ +k3~ be an 
estimated parameter and ts be the time needed to shift the oral curve to the 
left to line up with the intravenous curve then the corresponding extravascu- 
lar equation is Eq. (11). 
424 Wagner et  aL 
Source of Eq. (12) 
The postinfusion equation where an infusion at the rate k0 is put into 
compartment 1 over r hours and time is measured from the start of the 
infusion is Eq. (25). 
c k o ( k 2 1  - ~l)(k31 - ~ l ) ( e  + A I r -  1) e_~, , 
,~1 (Z2 - Zl)(Z3 - Zl) Vpr 
q ko(k21 -)~2)(k31 - )~2)(e +22~- 1) _22, 
e 
•2(Zl - Z2) (Z  3 - 22) Vpr  
_~ ko(k21 --/~3)(k31 -- ~3)(e +z3z- 1) e_A3 t (25) 
/~3(Zl --  Z3) (/~2 --/~3) Vp27 
Substituting for ko/Vp in Eq. (25) from Eq. (21), multiplying out the 
numerators of the three terms of Eq. (25), canceling the ;t~ in the numerator 
and denominator of the first term, then doing the same with ;t2 and •3 in 
the second and third terms, respectively, yields Eq. (12). 
Absorption Kinetics 
The Exact Loo-Riegelman method (6) with the Proost modifications 
(7) was applied to each set of extravascular data analyzed by Methods 2, 3, 
4, and 5 to obtain values of AT/Vp as a function of time. The asymptote, 
A~/Vp, of a plot of AT/Vp vs. time is theoretically equal to Co and, hence, 
as a result of Eq. (18) we obtain Eq. (26). 
A~ 
- klo" (A UC) (26) 
Vp 
In some cases one might expect absorption to be irregular and not 
readily describable by a mathematical function. In such a case only the plot 
of AT/Vp vS. t may be presented. However, in all cases where the new 
methods have been applied by us we have been able to fit the AT/V v vs. t 
data to one of Eqs. (28), (29), or (30) and the fraction absorbed, FA, vs. t 
data to one of Eqs. (31), (32), or (33), where 
FA =_AT/Vp _ AT/Vp _ A T  (27) 
A~/Vp kl0' (AUC) Ao~ 
AT/Vp = (A ~/ Vp) { 1 - e-  ka(t - -  tO)} (28) 
{ l (kl e-k2'-k2 e-k't)} (29) AT/Vp=(A~/Vp) 1 k , -k2  
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AT /ko~ 
FA = 1 - e -ka('-t~ (31) 
1 
FA = 1 (kl e-k2r e -~t) (32) 
kl -k2  
FA = (Ak~~ - to) (33) 
It should be noted for Eq. (30) that when t - t o  is equal to the time 
when the dose has been absorbed then ko ( t - t o ) = A ~ ;  the same thing is 
true for Eq. (33) in which case FA = 1 also. In Eqs. (28) and (29), A~/Vp  
was usually equal to kio(A UC). 
Equations (28) and (31) are for simple first-order absorption with a lag 
time, to; Eqs. (29) and (32) are for two consecutive first-order processes 
without a lag time, where, for example, kl could refer to dissolution and 
stomach emptying and k2 refer to absorption across the gastrointestinal 
barrier, or vice versa, in the case of oral administration. Eqs. (30) and (33) 
are for zero-order absorption; note that when AT/Vp is plotted vs. t - to the 
slope of the least squares line is ko/Vp and when FA is plotted against t -  to 
the slope of least square line is ko/A~.  
Reconstructions 
In this article on system analysis Veng Pedersen (33) stated: "Unfortun- 
ately, it is sometimes difficult and even impossible to reconstruct the basic 
drug level response from the parameters presented in pharmacokinetic stud- 
ies." In the course of this research we have determined absorption and 
disposition parameters from 50 sets of extravascular concentration-time 
data and have successfully made reconstructions using the parameters esti- 
mated by each of the methods. In each case such a reconstruction is a 
theoretical trend line drawn through a plot of the original concentration- 
time data and based on the complete compartment model elaborated by the 
stepwise procedure and the parameters which were estimated. The compart- 
ment models which were elaborated and the equations used in the reconstruc- 
tions are shown below. 
Mesoridazine (20 Sets) and Flurbiprofen (12 Sets) 
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Scheme 3. Model elaborated stepwise for both mesoridazine besylate and 
sodium flurbiprofen solution orally. 
reconstruction equation as Eq. (34). 
I(k2~ - Z , )  e -z'('-'~ (k21-Z2) e -z2('-'~ C=kaCo . . . .  (/!,2 - -  ,,~,) ( ka  - ~, , )  (,'t,1 - ,;L2) ( ka  - Z2)  (k21 - ka) e-~~176 1 
(34) 
Flunarizine (5Sets) 
The compartment model elaborated is shown as Scheme 4 and the 
reconstruction equation as Eq. (35) which was used for data for four patients 
showing first-order absorption and as Eqs. (36) and (37) which were used 
with one patient where the first-order input rate constant of Scheme 4 was 
ka 
_1 *,~ I I' _1 *,~ I ~  
2 ] I - 1  - I  I 3 
k lo  
Scheme 4. Model elaborated stepwise for ftunarizine administered orally. 
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changed to a zero-order rate constant, ko. 
1. ,'- [(k21 - 21)(k31 - 21) e - z ' ( t - '~  (k21 --  22)(k31 --  22) e -z~('-'~ 
c= (22-- zl)(z-----]- 21---5 (21 - 2 2 ) ( 2 ~ -  Z 2 ) ( k ~ -  Z2) 
-t (k21-23) (k31-Z3)  e -z3(t-t~ ( k 2 1 - k . ) ( k 3 1 - k ~ )  e -~ ( t - ' ~  
(-~1 ~ - k ~ ) ( ~  ] (35) (21 - -  2 3 ) ( ~  2 -  2 3 ) ( k  a -  23)  
During zero-order absorption 
(k21 - lt,1)(k31 - 21)  ( e + ; q ( t _ t o )  _ 1) e -x ' ( ' -~  
,~1 (22 --  Zl)(t~, 3 --  21 ) 
C =k~ -t (k21-  22)(k31-22)  (e+Z2(t_to)_ 1) e -z2(t-t~ (36) 
v~ z ~ ( z l  - z~) (z~  - 2~) 
H (k21 - 23)(k31 - ,~-3) (e+Z3(,-to) _ 1) e -z3('-'~ 
23(21 - ; t3)(22 - A,3) 
After zero-order absorption 
" ( k 2 1 - , ~ t ) ( k 3 1 - - X 1 )  (e+Z~(~_,o)_ 1) e - z~( ' - t~  
21(22  --  ~i,l) (,~, 3 - -  21 ) 
c=ko _~ (k21-22) (k31-L2)  (e+Z2(~_/o)_ 1) e -z2(t-t~ (37) 
Vp ,~ (21  - 22) (23  - Z2) 
-I" ( k 2 1 - 2 3 ) ( k 3 1  - ,~,3) ( e + ; t 3 ( r - t o )_  1) e - '1"3(t- t~ 
23(21 - 23) (22 - ,~3) 
Labetalol (9 Sets) 
The compartment model elaborated is shown as Scheme 5 and the 
reconstruction equations as Eqs. (38) and (39) 
ko ~ C k~o ~- 
Scheme 5. Model elaborated stepwise for labetolol administered in 
solution via intestinal infusion. 
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During zero-order input 
C ko(k21-XO(e  +z~t- 1) e -z't ko(kal-A~)(e +x2t- 1) e -z2t 
- + ( 3 8 )  
Zl(Z~- z,) Vp ,a,2(z~ - z~) G 
After zero-order input ceases at t = r 
c=ko(k21 - Al)(e +~'~- 1) e -z't  
Z~ ( Z2 - Zl) lip 
k0(k21 - X2)(e +z2r- 1) e -z2t 
+ (39) 
ZdZ2- ZI) lip 
Diazepam (4 Sets) 
The compartment model elaborated is shown as Scheme 6 and the 
reconstruction equation as Eq. (40). 
C-I~ 1 . .  ~ (k21-~l)(k31-s e -z't 
- 
( k 2 1  - ~ , 2 ) ( k 3 1  - ~,2)  e - z 2 t  
(Xl - ; t , 2 ) (k l  - X2)(k2 - ~2)( ,~ ,3  - ~ 2 )  
(kal - ~ , 3 ) ( k 3 t  - ;!,3) e -x~t 
(/~1 --/~3) (~2 -- ~3) ( k l  - X3)  ( k 2  - ) ,3)  
(k21 - k l ) (k31  - k l )  e - k ' t  
(XI - k0  (A,2 - k l )  (~,3 - k t ) ( k 2  - kl) 
(k21- k2)(k31-k2) e -k2t l (z, (40) 
S i m u l a t i o n s  
Three sets of concentration-time data were generated with the model 
of Scheme 3 and Eq. (34). The parameter to was made equal to zero in all 
cases, The three sets of data were derived using kl0, k12, k21, and k~ values 
very similar to those values which estimated from real flurbiprofen plasma 
concentrations measured following oral administration of a solution of the 
sodium salt of flurbiprofen and which were analyzed by the new methods 
(see Results section). We believe it is much more relevant to use parameter 
values in simulations similar to those estimated from real data than to use 
random numbers. For each data set 12 concentrations were generated corre- 
sponding to the times 0.1, 0.25, 0.5, 1.5, 2.5, 4, 6, 8, 12, 16, 24, and 32 hr 
which simulated what could be readily done experimentally. 
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Scheme 6. Model elaborated stepwise for diazepam administered orally 
in immediate-release tablets. 
Analysis  of  Real  Concentrat ion-Time Data  
Mesoridazine 
Data of Ganes (34) were used. Commercial tablets (Serentit | Sandoz) 
of 12.5, 25, and 50 mg (free base), containing the drug as mesoridazine 
besylate, were administered to normal human beings as single doses at 2- 
week intervals. Venous plasma samples were collected prior to drug adminis- 
tration and at 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 32, 48, and 72 hr 
following administration of the highest dose; the 10 and 15 hr samples were 
not collected following the two lowest doses. The unchanged drug was meas- 
ured by a sensitive and specific HPLC method described in detail by Ganes 
(34). 
Table III lists the times of the peak plasma concentrations (peak times) 
and the time of the first C, t pair used in the biexponential fits to Eq. (1). 
These were very difficult data sets to decide what points to use first for the 
biexponential fits. If  a point too near the peak was used then either a differ- 
ence of two exponential terms or a triexponential equation fit the data; a 
later point was then used as the first point and another biexponential fit was 
attempted; the process was repeated until a biexponential equation with two 
positive coefficients fitted the data set well. The appearance of a plot of the 
data also helped the process. 
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Table I l L  P e a k  T ime  and  Time of  F i r s t  D a t a  Po in t  for Biexponent ia l  F i t  to E q u a t i o n  (1) o f  
Downs lope  C, t D a t a  for Mesor idazne  Besylate 
Dose  
12.5 mg  25 mg 50 m g  
Peak  t ime  Fi rs t  da t a  Peak  t ime Fi rs t  da t a  Peak  t ime Fi rs t  da ta  
Subject  (hr)  po in t  (hr)  (hr)  po in t  (hr)  (hr)  po in t  (hr) 
1 1.5 3 2 4 2 8 
2 1 4 0.67 4 I 10 
3 . . . .  1.5 4 
4 0.67 3 1.5 4 4 8 
5 1 2 - -  - -  3 6 
7 1 4 - -  - -  1.5 8 
8 - -  - -  2 6 3 10 
11 3 6 1 4 - -  - -  
13 - -  - -  0.67 4 2 8 
The same data set with appropriate downslope starting time was then 
fitted to Eq. (5) in order to apply Method 3A and kl0 and ts were estimated 
using Eq. (5); the ~ and ~2 obtained in the biexponential fit to Eq. (1) were 
held constant when fitting to Eq. (5) was carried out. Values of k2~ and k~2 
were then estimated with Eqs. (3) and (4). Using this set of k~2, k21, and kl0 
values the Exact Loo-Riegelman method (6) with the modification of Proost 
(7) was then applied to all of the C, t data of the same data set; fraction 
absorbed values were then obtained with Eq. (27); these were fitted to Eq. 
(31) by nonlinear least squares with the program MINSQ (30) to estimate 
ka and to for Method 3A. 
Method 2 was applied by obtaining A UC with Eq. (6), M R T  with Eqs. 
(13) and (16) and using MIT= 1/ka, where ka was obtained by application 
of Method 3A. A new k~0 was then obtained with Eq. (2) and the correspond- 
ing k~2 and k21 values obtained with Eqs. (3) and (4) again. 
Method 4 was applied by substituting into Eq. (8) using the first time 
for the biexponential fit as the value of r, the A UC from Eq. (6), and B1, 
)q, and ~2 from the biexponential fit to Eq. (1). 
Reconstructions were made using the model of Scheme 3, Eq. (34), and 
the constants estimated by Method 3A. 
Flurbiprofen 
Data of Gonzalez (35) was used. Twelve normal volunteers were each 
administered 25 ml of a 2.5 mg/ml aqueous solution of sodium flurbiprofen 
followed by 6 oz. of water after an overnight fast and the subjects were 
fasted for 4 hr postdose. Venous plasma samples were collected predose and 
at 0.083, 0.167, 0.25, 0.33, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24, 30, 36, and 48 hr 
postdose. Unchanged flurbiprofen was assayed by a specific and sensitive 
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HPLC method with fluorescence detection described in detail by Szpunar 
(36). 
It was less difficult with the flurbiprofen data than with the mesoridazine 
data to decide which C, t pair should be the first data point for the biexpo- 
nential fit to Eq. (1). For Subjects 1 and 4-12, the 2-hr point was the starting 
point and for Subjects 2 and 3, the 4-hr point was used. Analyses were 
carried out on the 12 sets of C, t data as described above for the mesoridazine 
data. 
Reconstructions were carried out using the model of Scheme 3, Eq. 
(34), and the constants obtained via Method 3A. 
Labetalol 
Two hundred milligrams of labetalol HC1 in 40 ml of solution was 
administered to each of nine normal volunteers as an intestinal infusion over 
a 4-hr period via a small bowel intubation tube. This study was performed 
under contract for Schering Corporation. The venous plasma concentrations 
of labetalol measured in this study are listed in Table A of the Appendix. 
Since r = 4  in this case, M I T =  r/2 = 2hr and Methods 2 and 4 are most 
appropriate to estimate disposition parameters and were the only methods 
employed. Eqs. (2), (3), (4), and (13) were used for Method 2 and Eqs. (3), 
(4), (8), and (13) were used for Method 4. Labetalol concentrations from 
4-24 hr were used for the biexponential fittings to Eq. (1). 
Reconstructions were carried out using the model of Scheme 5, Eqs. 
(38) and (39), and the parameters estimated by Method 2. 
Flunarizine 
Flunarizine pharmacokinetics were first described by Kapetanovic et al. 
(37). They administered 30 mg single oral doses of flunarizine to 12 epileptic 
patients and drew plasma samples over a 32-day period. They fitted "post- 
absorptive" concentrations to a triexponential equation for each patient but 
did not specify which C, t data points were used. They also reported values 
of the disposition parameters k12, k21, k13, k31, and k~0 for the classical three- 
compartment model (Scheme 2) but apparently did not correct for the fact 
the postabsorptive oral data were fitted to the triexponential equation rather 
than bolus iv data as required by the equations they apparently used. 
In a study carried out by J. C. Sackellares in the Department of 
Neurology, The University of Michigan Medical School, five epileptic 
patients were administered single 30 mg oral doses of flunarizine and venous 
plasma samples were collected for a 70-day period postdosing. The plasma 
samples were assayed for flunarizine by the Epilepsy Branch, National Insti- 
tute of Neurological and Communicative Disorders and Stroke, Bethesda, 
MD. The plasma concentrations are listed in Table B of the Appendix. The 
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first downslope data point taken for the triexponential fit to Eq. (10) was 
7.9, 6, 6, 6, and 12 hr for subjects M01LH, M07CL, M02SL, M03PS, and 
M05AL, respectively. The Cr value for each data set was obtained by substi- 
tuting the time value indicated by the asterisk in Table B of the Appendix 
into Eq. (10) and the AUC was obtained with Eq. (6). 
Method 3A was applied by fitting postabsorptive data to Eq. (11) using 
the ~L~s of Eq. (10) as constants and estimating kl0, Z and ts. Equations of 
Gibaldi and Perrier (3) were used to obtain k21, k31, k12, and k~3. The 
Exact Loo-Riegelman method (6) with the Proost modification (7) was then 
applied to all of the C, t data of the same data set and fraction absorbed 
values were estimated with Eq. (27). The FA, t data were computer-fitted to 
Eq. (31) to estimate ka and to for Method 3A. 
Method 3B was applied using Eq. (11) and estimating ts, k~o, Z, ~ ,  
,~2, and ~13 by the method of least squares and the program MINSQ (30). 
Method 5 was applied by fitting postabsorptive C, t data to Eq. (12) 
with r, Z, and kl0 as estimated parameters. The remainder of the disposition 
rate constants were then estimated as described above for Method 3A. 
The Exact Loo-Riegeman method (6) with the Proost modification (7) 
was then applied to all the C, t data of each data set using the disposition 
parameters obtained by Methods 3A and 5 then the AT/Vp data were treated 
as described above for Method 3A. 
Reconstructions were performed using the model of Scheme 4, Eq. (35), 
and the constants obtained via Methods 3A and 5. 
Diazepam 
Data used were those given in detail by Kaplan et al. (38). Four healthy 
male volunteers each received 10 mg of diazepam by bolus iv injection and 
10 mg orally. Blood concentrations were measured at 1, 2.5, 5, 10, 15, 20, 
30, and 45 min and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, and 48 hr after iv dosing 
and at 15, 30, and 45 min and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, and 48 hr 
after oral dosing. Although Kaplan et al. (38) reported coefficients and 
exponents of triexponential fits of the iv data, as well as k12, k21, k13, k3~, 
and k~0 of the model of Scheme 2, we refit these data and found our fits had 
lower sums of squared deviations than those reported (38). The disposition 
parameters for Method 1 were estimated from the coefficients and exponents 
of the triexponential equation using the equations of Gibaldi and Perrier 
(3). 
There were nine pairs of postabsorptive oral C, t data in the 2- to 
24-hr period for each subject and each set was computer-fitted to Eq. (10) 
using the program RSTRIP (30) with equal weights. Disposition parameters 
for the model of Scheme 2 were estimated by Methods 3A and 5 by similar 
procedures as described above under flunarizine. Using the disposition 
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parameters estimated by these methods the Exact Loo-Riegelman method 
(6) with the Proost modification (7) was applied to all of the C, t data of 
each data set. FA values were then obtained with Eq. (27) but attempted 
fittings of the FA, t data to Eq. (32) gave "divide by zero" errors with the 
program MINSQ (30). Also, it was found that the asymptote of plots of 
AT/Vp vs. time was not equal to k~o (A UC) for Methods 1 and 3A but were 
for Method 5. The AT/Vp values were fitted to Eq. (29) with A~/Vp, k~, 
and k2 as estimated parameters. 




Table IV gives results of application of Methods 3A and 5 to the error- 
free data generated as described under Simulations in the Experimental 
section. The Exact Loo-Riegelman method (6,7) was applied to the C, t 
data using the disposition parameters estimated by Methods 3A and 5. The 
AT~ Vp data were fitted to Eq. (28) and the estimated A~/Vp and ka values 
are also listed in Table IV. Using Method 3A the mean error in the parameter 
estimates was 1.28% and the mean absolute error was 3.0%. Using Method 
5 the mean error was 1.95% and the mean absolute error was 4.81%. The 
largest errors were in the ka estimates. The measures of fit, namely, r 2 and 
Model Selection Criterion (MSC) were all very high in these fittings. 
Figure 1 explains Method 3A and Fig. 2 explains Method 5. These 
figures are based on the parameter values of Set 1 in Table IV. These methods 
are explained by the captions of these two figures. 
Using the parameters estimated by Method 3A in Table V the ratios 
ka/2l were 23.3, 24.2, and 47.2 for Sets 1, 2, and 3, respectively. The ratio 
k,/;~2 was 7.62, 7.17, and 5.67 for Sets l, 2, and 3, respectively. For these 
simulations to=0 and Eq. (34) may be written as Eq. (42), where B3 = 
Bt +B2. 
C = BI e- ~lt + B2 e- Z2t- B3 e -z3t (42) 
The following fractional area was calculated: 
B3/k, 
Fractional area 1 - (43) 
Bl B2 B3 
,~1 )-2 k~ 
Using the estimated parameters by Methods 3A in Table IV the frac- 













































































































































































































































































































































































































































































/0.429 Hr TIME SHIFT 
~--- PO CURVE 
I I I I I I 
2.0 4.0 6.0 B.0 10.0 12.0 
TIME {HOURS) 
14.0 
Fig. 1. Simulation which explains Method 3A. The model of  
Scheme 1 and the rate constants of  Set 1 in Table IV were used. 
The iv curve and points (O)  are based on Eq. (17). The po 
points (V]) are based on Eq. (34) with to = 0. The postabsorptive 
po data from 2.5-32 hr (only the 2.5-12 hr data are shown in 
the figure) were computer-fitted to Eq. (5) with the estimate of  
& = 0.429 hr. Thus,  the fitting indicates that  a shift of  the po 
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POST INFUSION CURVE 
~ 'to 12 Hr 
~UR!NG INFUSION CURVE ~ 
I I I ~ --I : 
2.0 4.0 6.0 8.0 10.0 12.0 
TIME (HOURS) 
Fig. 2. Simulation which explains Method 5. The model of  
Scheme 1 and the rate constants  of  Set 1 of  Table IV were used. 
The postabsorptive po data (A points in the figure ) from 2.5- 
32 hr (only the 2.5-12 hr data  are shown in the figure) were 
computer-fitted to Eq. (9) and r=0 .815  hr was estimated. This 
fit was based on the oral data being treated as postinfusion 
data. Hence, one can infer the infusion curve (O  points in the 
figure) from 0-0.815 hr followed by postinfusion fall off (Fq) 
points) from 0.815 to 2.5 hr  which was based on Eq. (19). 
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Thus, the new methods work satisfactorily with the model of Scheme 3 when 
the ratios ka/)`l and ka/)`2 and the fractional areas have magnitudes as given 
above. Additional simulations (not shown) indicated that as the ratios ka/ 
).1 and ka/)`2 decreased and the fractional area increased, the accuracy of 
estimates of the disposition parameters kl0, k21, and k~0 decreased. 
Analysis of Real Concentration-Time Data 
Mesoridazine ( Biexponential Disposition) 
Table V lists the estimated parameters of the model of Scheme 3 
obtained by Methods 2, 3, 3B, and 4 for the 20 sets of human mesoridazine 
data analyzed. The overall mean disposition parameters were kl0 = 
0.275 hr -  1, k12 = 0.182 hr -  1 and k2m = 0.168 hr-  1. The overall mean absorp- 
tion parameters were ka = 1.21 hr -  1 and to = 0.206 hr. There were 280 param- 
eter values estimated from the mesoridazine data. For each disposition 
parameter both the mean and range obtained by Methods 2, 3, 3B, and 4 are 
similar. None of the parameters estimated appeared to be dose-dependent. 
The means of the ka/)`l ratios were 21.5, 27.1, and 13.0 for the 12.5, 25, 
and 50 mg doses, respectively. The means of the ka/)`z ratios were 2.52, 6.64, 
and 3.13 for the 12.5, 25, and 50 mg doses, respectively. 
Flurbiprofen (Biexponential Disposition) 
Table VI lists the mean, CV, and range of k12, k21, and kl0 o'f the model 
of Scheme 1 estimated by Methods 2, 3A, 3B, 4, and 5 for flurbiprofen in 
12 subjects following oral administration of a solution of sodium flurbipro- 
fen. There were 300 parameter values estimated from the flurbiprofen data. 
Table VII lists results of ANOVA of the disposition parameters of 
flurbiprofen. The mean square for methods was not significant (F=0.08, 
p >  0.25); almost all the variation was associated with subjects and rate 
constants. The absorption and disposition parameters of flurbiprofen were 
remarkably similar when determined by the different methods as can be seen 
by comparing the mean and range of values for each parameter by the five 
methods (Table VI). 
In Method 3A one iterates for the parameters kl0 and ts of Eq. (5) but 
holds )̀ 1 and )`z constant after the latter parameters have been obtained in 
the biexponential fit to Eq. (1). In Method 3B one iterates for all the param- 
eters )`1, )`2, kl0, and ts of Eq. (5). In Method 5 one iterates for kl0 and r of 
Eq. (9) but hold )̀ 1 and )`2 constant as in Method 3A. We used the coefficient 
of determination (r z) and the MSC as measures of fit as well as the standard 
deviation of the estimated parameter, s, or the corresponding coefficient of 
variation, s/P, where P is the estimated parameter value. One expects s and 
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Table VI. Flurbiprofen Parameters of Twelve Subjects 
Parameter Method )( CV (%) Range 
k12 (hr-  l) 2 0.0780 48.9 0.0422-0.156 
3A 0.0779 46.6 0.0419-0.145 
3B 0.0811 45.4 0.0420-0.153 
4 0.0750 48.9 0.0379-0.149 
5 0.0790 48.7 0.0398-0.158 
k21 (hr-  1) 2 0.179 19.8 0.132-0.230 
3A 0.179 21.2 0.137-0.235 
3B 0.186 18.4 0.137-0.234 
4 0.169 18.5 0.131-0.218 
5 0.183 21.0 0.140-0.234 
klo (hr-  ~) 2 0.237 17.1 0.150-0.308 
3A 0.237 17.6 0.151-0.291 
3B 0.234 17.0 0.150-0.291 
4 0.249 17.5 0.156-43.317 
5 0.232 16.8 0.152-0.292 
k. (hr-  1) 2 8.14 68.8 1.97-18.4 
3A 7.59 67.6 2.13-14.9 
3B 8.24 65.3 2.17-15.9 
4 7.26 66.9 1.83-14.0 
5 8.18 69.0 1.70--14.7 
to (hr) 2 0.0394 83.0 0-0.109 
3A 0.0358 97.6 04). 110 
3B 0.0397 83.5 0-0.110 
4 0.0355 98.1 0-0.109 
5 0.0373 93.2 0-0.1 l0 
~,1 (hr-  1) 3A 0.110 11.4 0.0877-0.128 
~-2 (hr-J)  3A 0.384 22.7 0.3064).543 
Table VII. ANOVA of klo, k12, and k21 Values of Flurbiprofen 
Source of variation df SS MS F 
Subjects 11 0.16137 0.01467 29.4 
Rate constants 2 0.78461 0.39231 787. 
Methods 4 0.0001624 0.0000406 0.08 (p>  0.25) 
Residual 162 0,080713 0.0004982 
Total 179 1.0268554 
the number of parameters estimated and hence the degrees of freedom. For 
the flurbiprofen fits and the estimation of klo, Methods 3A, 3B, and 5 gave 
mean s/P ratios of 0.0244, 0.0590, and 0.0247, respectively. For the fits to 
Eq. (31) to estimate ka the mean s/P values were 0.183, 0.237, and 0.245, 
respectively, when disposition parameters of Methods 3A, 3B, and 5 were 
used. 
Figure 3 shows the fit of C, t data of Subject 3 given flurbiprofen to 
Eq. (5) by Method 3A. Figure 4 shows the fit of the absorption data of the 
same subject after Method 3A parameters had been used to generate the 
absorption data via the Exact Loo-Riegelman method (6,7). Figure 5 shows 
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Fig. 3. Fit of the data of Subject 3 given flurbiprofen to Eq. 
(5) with Method 3A. The parameters kio=0.235 hr -1 (s= 
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1.0 2.0 3.0 4.0 5.0 6.0 
TIME (HOURS) 
Fig. 4. Absorption plot for Subject 3 given flurbiprofen to 
Eq. (31) using disposition parameters obtained with Method 
3A. The parameters ka= l . 84h r  -~ (s=0.250) and to = 
2.7 x 10 -6 (s=0.0388) were estimated. 
reconstruction of the original data of the same subject based on Eq. (34). 
After such reconstructions were made the C, t data were fitted by nonlinear 
least squares and the program MINSQ (30) to Eq. (34). Such fits gave only 
slight improvement in the closeness of the trend line to the points compared 
with the reconstructions. This is reflected by comparing r 2 and M S C  values 
for the reconstructions and fittings. The reconstructions gave mean (and 
range) r 2 values of 0.958 (0.948-0.996), while the fittings gave 0.983 (0.928- 
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~ 12.0 







n 0 10 20 90 40 50 
TIME (HOURS) 
Fig. 5. Reconstruction of the original data of Subject 3 given 
flurbiprofen orally. The solid line is based on the model of 
Scheme 3, Eq. (34) and the parameter values k~2=0.145 hr- 1, 
k21=0.178h r l, kj0=0.285hr-i  k = l . 8 4 h r - l ,  and to = 
2.7 x 10 6. 
0.998) ; the corresponding MSC values were 6.54 (4.26-8.05) for the recon- 
structions and 7.85 (5.41-10.32) for the fittings. 
The mean ka/mean ~,~ = 69 and the mean ka/mean ,~2 = 20 by Methods 
3A using values in Table VI. The individual subject fractional areas [Eq. 
(43)] were of the same order of magnitude as reported above for the 
simulations. 
Flunarizine ( Triexponential Disposition) 
Table VIII lists the disposition parameters of the model of Scheme 2 
estimated by Methods 3A and 5 for the five epileptic patients given 30 mg 
single oral doses of flunarizine. Absorption parameters of Eq. (28) are also 
listed in Table VIII. 
Table IX gives results of ANOVA of the disposition rate constants of 
flunarizine. The mean square for methods was not significant (F= 0.00017, 
p > 0.25). The absorption and disposition parameters of flunarizine were very 
similar when determined by the two methods as can be seen by comparing the 
values in Table VIII. 
With the flunarizine data Method 3A was superior to Method 5 in the 
estimation of kl0 since the s/P ratio for the former averaged 0.107 (range 
0.0702-0.178) compared with 0.552 (range 0.139-1.08) for the latter. 
The 2~1 values are also listed at the bottom of Table VIII. For the four 
patients who exhibited first-order absorption the average values of ka/),j, 
ka/~2, and ka/;c3 were 970, 18.4, and 2.49, respectively. Fractional area 
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Table VIII. Flunarizine Parameters in Five Epileptic Patients . 
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Subject 
Parameter Method M01LH M07CL M03PS M05AL M02SL 
k~0 (hr -1) 3A 0.0615 0.0467 0.0612 0.230 0.0383 
5 0.0640 0.0485 0.0501 0.193 0.0331 
kl2 (hr 1) 3A 0.0736 0.0863 0.0745 0.119 0.0494 
5 0.0475 0.0824 0.0772 0.146 0.0556 
kl3 (hr -1) 3A 0.154 0.091 0.107 0.124 0.0494 
5 0.188 0.0959 0.114 0.123 0.0657 
k21 (hr -1) 3A 0.0581 0.0615 0.564 0.0901 0.0343 
5 0.0507 0.0586 0.0575 0.100 0.0372 
k31 (hr -I)  3A 0 . 0 0 4 0 4  0 .00166  0 .00162  0 .00404 0.0224 
5 0.00445 0 .00168  0 .00194  0 .00431 0.00259 
k~ (hr - j)  3A 0.527 0.877 0.893 0.708 61.6 
5 0.688 0.780 0.970 0.402 57.9 
to (hr) 3A 0.012 0.366 0.556 1.18 0.929 
5 0.443 0.352 0.557 0.797 0.803 
A,~/Vp (ng/rnl) 3a 164 123 173 226 199 
5 182 129 164 262 190 
s (hr -1) 3a 0.00110 0.000553 0.000579 0 . 0 2 6 0  0.00829 
~2 (hr- 13 3a 0.0421 0.0342 0.0365 0.0464 0.0225 
~3 (hr -1) 3a 0.311 0.252 0.264 0.499 0.171 
Table IX. ANOVA of Flunarizine Disposition Rate Constants 
Source df SS MS F p 
Subjects 4 0.03089 0.00723 7.32 <0.001 
Rate constants 4 0.06230 0.01558 15.8 <0.001 
Methods 1 0.00000169 0.000000169 0.00017 <0.25 
Total 49 0.13270 
values  ob ta ined  f rom Eq. (35) were o f  the same o rde r  o f  magn i tude  as those  
o f  the  s imula t ion  r epo r t ed  above.  
Labetalol (Zero-Order Input and Biexponential Disposition) 
Table  X lists the d ispos i t ion  pa rame te r s  o f  the t w o - c o m p a r t m e n t  open  
mode l  (Scheme 1) o f  the ind iv idua l  subjects  given labe ta lo l  by  cons tan t  
ra te  intes t inal  infus ion over  4 hr. Overa l l  m e a n  ra te  cons tan ts  were k~0 = 
0.319 hr  -1, k12=0.558 hr  -1, and  k21 =0 .298  hr  -1. Two- fac to r  A N O V A s  
ind ica ted  tha t  t h e  mean  square  for  me thods  was no t  significant ( p  > 0.10) 
for  each ra te  cons tan t  when d a t a  in Tab le  X were analyzed.  
The  Exac t  L o o - R i e g e l m a n  m e t h o d  (6,7) was app l ied  to the C, t d a t a  
in the 0 -4  hr  range and  A~/Vp was found  to be equal  to klo ( A U C )  in each 
case, hence Eq. (27) was used to  es t imate  FA values.  F o r  each o f  the nine 
subjects  the least  squares  FA vs. t line forced th rough  the or ig in  was 
ob t a ined ;  the  s lopes are the input  rates  (ko/A~ in f r a c t i o n / h r )  l isted in the 
last  two co lumns  o f  Tab le  X. The  theore t ica l  r a t e =  1 / 4 = 0 . 2 5 0  hence the 
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Table X. Labetalol Disposition and Input Rate Constants (Methods 2 and 4) 
A UMC Input rate 
A UC klo (hr- t) kt= (hr- 1) k21 (hr- l) (fraction/hr)a 
Subject (hr) V v (L) 2 4 2 4 2 4 2 4 
1 15.17 1465.0 0.180 0 .229  0.260 0 .333 0.105 0.163 0 .257  0,261 
2 10.15 2910.0 0 .211 0 .208  0.164 0.164 0.216 0.219 0 .288  0.274 
3 12.65 2171.0 0.200 0.232 0.254 0,347 0.165 0.232 0.264 0.268 
4 9.74 1420.0 0.252 0 ,249  0 .241  0,259 0.240 0.269 0 .258  0.264 
5 8.49 1645.0 0.399 0 .462  0 .628  0 ,785  0.355 0.416 0.254 0.239 
6 11.34 865 .3  0 .492  0 .518  1 .447  1,453 0.378 0.387 0.252 0.243 
7 9.71 2287.0 0.292 0.260 0.270 0 .217  0.241 0.207 0.248 0.254 
8 10.42 1366.0 0 ,308 0,329 0 .481  0 .523  0.306 0.302 0 .245  0.238 
9 8.35 617 .0  0 .429 0.494 1 .024  1 .180 0.564 0.587 0 .263  0.252 
.g 10.67 1638.0 0.307 0 .331  0.530 0 ,585 0.286 0.309 0 .259  0.255 
C V ( % )  20.1 43.8 36.0 37.9 82.5 78.6 47.5 43.1 4.88 5.09 
aTheoretical value = 0.250. 
mean rates of 0.259 and 0.255 for Methods 2 and 4, respectively, have biases 
of 3.6 and 2.0%, respectively; there were low coefficients of variation of 4.88 
and 5.09%, respectively, also. Figure 6 shows an example of one of the input 
plots. The small scatter of the points about the line for both methods and 
all nine subjects may be gauged from the fact that for Method 4 the s/P 
ratio averaged 0.0306 with a range of 0.0123-0.0605 and similar results were 
obtained with Method 2. 
Figure 7 is a reconstruction of the labetalol C, t data of Subject 6 using 
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Fig. 6. Input plot for Subject 6 given labetalol based on dispo- 
sition parameters obtained with Method 2. The slope of  the 
line is the input ko/A~ value and is equal to 0.252 with s=  
0.0123; the theoretical input rate is 0.250. 
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Fig. 7. Reconstruction of the labetalol data of Subject 6 where 
the disposition parameters had been obtained via Method 2 
(Table X) and Eqs. (38) and (39) were used. 
Diazepam ( Triexponential Disposition and Biexponential Absorption) 
Table XI lists the disposition and absorption parameters estimated from 
oral C, t data of four subjects who were administered 10 mg doses of 
diazepam. Ar/Vp values obtained via the Exact Loo-Riegelman method 
(6,7) were computer-fitted to Eq. (29) and the estimates of kl, k2, and Aoo/ 
Vp obtained are summarized in Table XI. 
Table XII gives results of ANOVA of the diazepam disposition param- 
eters for Subjects 1-3 only since Subject 4 gave bi- rather than triexponential 
disposition after iv administration. Thus disposition was nonconstant for 
Subject 4. The mean square for methods was not significant (F=0.33, 
p >  0.25) indicating that disposition was constant intrasubject for Subjects 
1-3. Table XIII gives results of ANOVA of the diazepam absorption param- 
eters of the four subjects. Again the mean square for methods was not 
significant (F= 0.45, p > 0.25). 
The overall mean rate constants for diazepam were klo=0.123 hr -1, 
k12= 1.77 hr -l, k13=0.384hr -1, k21=0.959 hr -1, k31=0.0629 hr -1, kl = 
1.66 hr-  1, and k2 = 5.05 hr- t. 
In the estimation of kl0 of diazepam Methods 3A and 5 gave mean s~ 
P ratios of 1.29 and 1.52, respectively. In the estimation of Z, Methods 3A 
and 5 gave mean s/P ratios of 0.934 and 1.25, respectively. Hence, Method 
3A was superior to Method 5 from this point of view, but the difference 
between the methods was not nearly as great as in the case of flunarizine. 
In the case of the model of Scheme 6 and the five-term polyexponential 
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Table XII. ANOVA of Disposition Parameters of Diazepam for Subjects 1-3 a 
Source df SS MS F p 
Subjects 2 0.6036 0.3018 2.57 
Rate constants 4 14.8740 3.7185 31.6 
Methods 2 0.0782 0.0391 0.33 
Residual 36 4.2352 0.1176 
Total 44 19.7910 
>0.25 
aSubject 4 could not be included since Method I gave biexponential rather than triexponential 
disposition. 
Table XIII. ANOVA of Diazepam Absorption Parameters in Four Subjects 
Source df SS MS F p 
Subjects 3 101.8286 33.9429 3.41 
Parameter 2 223.1167 111.5584 11.2 
Methods 4 18.0155 4.5039 0.45 
Residual 50 497.2930 
Total 59 840.2538 
>0.25 
done using Eqs. (42) and (43) based on the model of Scheme 3. Intravenous 
diazepam data was fitted by nonlinear least squares using the program 
RSTRIP (30) to the triexponential Eq. (44). 
C= Cl e-)~t + C2 e-Z2t + C3 e -z3t  (44) 
From C~s and Zis of the four subjects a different Fractional area 2 was 
estimated as follows 
Fractional area 2 -  C1/A,l 
"~1 "~2 ~3 
(45) 
The five-term polyexponential Eq. (40) for oral administration may be 
written as Eq. (46). 
C= B1 e-'~lt + B2 e -  Z2' + B3 e-X3t + B4 e-klt + B5 e -k2r (46) 
From the Bis and A.,-s of the four subjects given diazepam orally (parameters 
which were needed are shown in Table XI) a Fractional area 3 was estimated 
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as follows 
B1/2l 
Fractional area 3 = (47) 
gl+B2_t_n3q_n4wfl5 
A,l ~2 ~3 kl k2 
The intravenous data gave a mean Fractional area 2 of 0.894 with a 
coefficient of variation of 11.2%. The oral data gave a mean Fractional area 
3 of 0.891 with a coefficient of variation of 21.9%. This indicates that the 
intravenous and oral data were very comparable. Now 1-0.895 =0.105, a 
value very similar to the Fractional area 1 reported above under Simulations 
and also under Flurbiprofen. 
Figure 8 shows reconstructions of the oral diazepam data of Subject 3 
using parameters estimated by the three methods. The peak concentration 
was underestimated in each case. The same type of underestimation occurred 
with data of the other three subjects. However, when all four data sets were 
fitted by nonlinear least squares to a five-term polyexponential equation 
using the program RSTRIP (30) the same type of underestimation of the 
peak concentration occurred in each case. 
Evidence that the new methods are superior to polyexponential fitting 
as done classically was provided by the diazepam results. Figure 9, upper 
panel, shows a log-log plot of the exponent (~1) obtained by triexponential 
fitting of postabsorptive oral diazepam data to Eq. (10) vs. the exponent 
(~1) obtained by triexponential fitting of bolus iv diazepam data to Eq. (44) 
for all four subjects. The least squares line is: in Y-- 1.096 In X-0 .217  with 
r 2=0.976; the corresponding line without logarithms is: Y =  
0.991 X+0.0413 with r2=0.911. There are only 11 rather than 12 points in 
each of these figures since the intravenous data of Subject 4 was fitted by a 
biexponential rather than a triexponential equation. Figure 9, lower panel, 
shows a log-log plot of the exponent (~1 or k~) obtained from the RSTRIP 
(30) five-term polyexponential fit of all the C, t oral data vs. the exponent 
(~1) obtained by triexponential fitting of bolus iv diazepam data for all four 
subjects. The least squares line is: In Y = 0.7295 In X - 0.992 with r 2 = 0.738 ; 
the corresponding line without logarithms is: Y = 0.292 X + 0.136 with r 2= 
0.673. The upper panel of Fig. 9 supports the lack of significance of the 
methods mean square of Table XII. With the five-term RSTRIP fit of the 
oral data it was difficult to assign each of the five exponents to disposition 
or absorption and the lower panel of Fig. 9 is about the best results which 
could be obtained. Thus with triexponential fitting of postabsorptive C, t 
data the exponents obtained correlate much better with the exponents 
obtained in fitting iv data of the same subjects than do the exponents 
obtained in classical fitting of all C, t data to a polyexponential equation. 
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Fig. 8. Reconstructions of the diazepam C, t data of  Subject 
3 using parameter values estimated by Methods 1 (top), 3A 
(middle), and 5 (bottom). The peaks were underestimated by 
all methods (see text). 
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Fig. 9. Evidence from the diazepam results that the new method 
o f  f i tt ing p o s t a b s o r p t i v e  oral  d a ta  is bet ter  t h a n  the  c lass ica l  
m e t h o d  o f  p o l y e x p o n e n t i a l  f itt ing o f  a l l  C ,  t data .  See  text  at 
e n d  o f  R e s u l t s  s e c t i o n  for  detai ls .  
DISCUSSION 
Advantages and Disadvantages 
The advantages of  the new methods are: 
1. Multicompartmental model disposition parameters are obtained 
from extravascular data without intravenous data obviating any assumption 
of constancy of disposition as in classical methods. 
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2. Absorption analysis can follow one or more disposition methods 
leading to elaboration of a complete compartment model from a single set 
of extravascular concentration-time data. 
3. Existing microcomputer software available in U.S. market is satisfac- 
tory to apply the methods. 
4. Once the absorption and disposition parameters have been estimated 
a reconstruction trend line may be drawn through the original C, t data. 
5. Once the complete compartment model has been elaborated from a 
set of extravscular C, t data then one can infer intravenous C, t data and 
derive parameters of system analysis (33,39-43) from extravascular data. 
6. Absorption plots may be made from multicompartmental extravas- 
cular data only, providing quantitation in determining the effects of formula- 
tion factors on performance of rapid release dosage forms in animals and 
human beings. 
7. The true normalized input rate may be estimated as evidenced by 
our results with labetalol. 
8. If constancy of disposition is assumed one may use the new methods 
with C, t data from a rapid-release dosage form such as a solution to deter- 
mine disposition parameters then use these with C, t data from a sustained- 
release dosage form to obtain absorption kinetics of the sustained-release 
dosage form. Thus, intravenous administration is avoided. 
The disadvantages of the new methods are: 
1. They are only applicable to linear data~ 
2. They are only applicable to C, t data obtained from rapid-release 
dosage forms. Ratios ka/2~l and ka/A2 and fractional areas have been 
reported and aid in quantitating how rapid absorption must be. 
3. They do not determine absolute bioavailability. 
4. The methods provide the wrong compartment model if there are 
vanishing exponential terms (44). 
Preferred Methods 
When one has no prior knowledge of input kinetics, then Method 3A 
is the preferred method. Method 3A produced smaller standard deviations 
of estimated parameters than Method 5. When input is known to be zero 
order and the input time, r, is known then Methods 2 and 4 are preferred 
as in the case of labetalol administered by intestinal infusion. 
Method 3B gave much larger standard deviations of the estimated 
parameters than Method 3A because the number of parameters estimated 
with Method 3B is larger, and hence the degrees of freedom smaller, than 
with Method 3A. However, the parameter values estimated via Methods 3A 
and 3B from the same set of data were not significantly different. 
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Absorption Kinetics 
Fifty sets of real extravascular C, t data were analyzed, each set by from 
two to six different methods, making a total of 198 compartment model 
analyses. In all cases absorption was described well by one of three models, 
namely, either simple first-order, two consecutive first-order processes, or a 
zero-order process. However, the description of absorption by a kinetic 
equation is not essential to the process and, conceivably, one could limit 
analysis of a set of C, t data to a plot of AT/Vp vs. time, which could not 
be described by a simple kinetic equation. 
Constancy of Disposition 
Data from the literature which are summarized in Tables I and II indi- 
cate that disposition is often not constant intrasubject. Our analysis of the 
diazepam data, where intravenous as well as oral data were available, indi- 
cate that disposition was constant intrasubject for 3 of 4 subjects. The impor- 
tant point is that the new methods provide a means of testing the hypothesis 
















Analysis of variance. 
Area under the C, t curve from zero to infinite time. 
Area under the first moment curve [see Eq. (13)]. 
The total amount of drug which reaches the systemic 
circulation = F. D. 
The amount of drug which reaches the systemic 
circulation to specific time T. 
The coefficient of the ith term (i= 1, 2, or 3) of the 
polyexponential equation fitting extravascular data. 
The observed drug concentration (in plasma, serum, or 
whole blood). 
The coefficient of the ith polyexponential term when 
bolus intravenous data are fitted. 
Clearance = D/A UC of total drug. 
Clearance of free drug = D/A UC of free drug. 
Renal clearance. 
The observed drug concentration at specific time T. 
The model-predicted drug concentration at specific time 
T. 
Coefficient of variation = 100 • (standard deviation/mean) 
for an array of numbers. 










A UMC/A UC 
MIT  





Dose of drug. 
Bioavailability 
Fraction of the available dose (F-D.) [Eq. (27)]. 
Disposition rate constants. 
First-order model rate constant. 
Absorption rate constants when absorption is 
biexponential. 
Absorption rate constant when absorption is 
monoexponential. 
A zero-order input rate constant (mass/time). 
Exponent of polyexponential equation (i= 1, 2, or 3). 
The mean residence time of the body after extravascular 
administration including the MIT. 
The mean input time from the absorption or input site(s) 
(45). 
The mean residence time = (A UMC/A UC) - MIT. 
The number of parameters estimated in a nonlinear least 
squares fitting. 
The parameter value estimated in a nonlinear least 
squares fitting. 
The coefficient of determination = 
1 - E  dev2/s~ where s 2 = E  y 2  (• xy)Z/n).  
The standard deviation of an estmated parameter in 
nonlinear least squares fitting. 
MSC In 
n 
Zi=, wi(gob.i- robs) 2 









Time after administration. 
The lag time before absorption apparently commences. 
The time needed to shift the postabsorptive oral curve to 
the left so it coincides with the bolus intravenous curve 
(see Fig. 1). 
Some specific time t. 
The duration of an infusion or zero-order input [see 
Methods 4 and 5 and Eqs. (8), (9), and (12)]. 
The volume of the central (~1)  compartment. 
Volume of distribution beta = Va area = D/1 (A UC). 
Weight of ith data point in a nonlinear least squares fit. 
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T h e  coef f ic ien t  o f  t h e  i th  p o l y e x p o n e n t i a l  t e r m  w h e n  
p o s t i n f u s i o n  d a t a  h a v e  b e e n  f i t ted .  
k21 + k31. 
APPENDIX 
Table A. Plasma Concentration of Labetalol in Nine Subjects 
Plasma concentration of labetalol (ng/ml) 
Time 
(hr) 1 2 3 4 5 6 7 8 9 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.50 17.77 15.28 12.59 1 7 . 0 1  10.84 16.14 6.83 8.05 24.85 
1.00 34.96 29.40 16.70 40.33 17.74 23.51 19.96 28.34 40.48 
1.50 37.71 25.18 23.19 43.40 20.67 30.29 25.58 25.92 63.28 
2.00 45.49 29.99 36.76 47.02 24.58 35.27 30.74 26.27 58.16 
2.50 51.37 33.72 37.94 49.01 22.80 41.43 32.02 40.12 68.72 
3.00 52.02 40.99 40.09 75.58 25.34 44.03 36.39 38.12 68.01 
3.50 55.51 31.30 41.55 59.83 44.16 45.87 42.30 70.43 82.52 
4.00 57.61 34.04 36.22 59.56 34,97 48.76 42.29 56.38 76.03 
4.50 44.34 36.72 27.76 53.58 25.80 32.06 37.15 42.25 56,55 
5.00 35.50 21.92 28.52 42.41 20.22 27.22 33.18 33.87 52.95 
6.00 32.00 28.46 18.18 35.15 16.58 22.91 18.44 26.62 45.11 
8,00 18.78 16.32 17.02 23.77 11.98 18.75 14.43 18.06 32.54 
10.00 16.98 9.45 12.43 21.58 9.37 15.64 12.27 15,65 23.85 
12.00 12.76 9.78 10.12 14.50 6.42 11.81 8.61 10,12 18.44 
16.00 9.41 7.67 6.76 9.84 4.62 9.29 4.71 10,48 10.58 
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